Health Tech Company Forms Massive Artificial Intelligence Partnership
Health Tech Company Forms Massive Artificial Intelligence Partnership
Foxo Technologies Teams Up with KR8 AI To Develop Revolutionary Epigenetic Application.
This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.
In an exciting development for the health technology industry, Foxo Technologies Inc., a Delaware corporation, has entered into a Master Software and Services Agreement with KR8 AI Inc., a Nevada corporation. This partnership is set to revolutionize the way we approach health, wellness, and longevity.
The agreement, which was effective from January 12, 2024, grants Foxo Technologies a limited, non-sublicensable, non-transferable perpetual license to use KR8 AI's products. The aim is to leverage these products to develop, launch, and maintain applications based on Foxo's epigenetic biomarker technology. The goal is to create an AI machine learning epigenetic application that could significantly enhance health, wellness, and longevity.
Foxo Technologies is a leading player in the world of health technology. It uses advanced technologies to develop solutions that enhance health and wellness. Foxo's Interim CEO and Interim CFO are both equity owners of KR8 AI Inc., demonstrating a strong connection between the two companies.
KR8 AI Inc., on the other hand, is a renowned name in the artificial intelligence industry. Its innovative products and services have made it a trusted partner for businesses across various sectors.
A Groundbreaking Partnership
This collaboration will enable Foxo Technologies to use KR8 AI's cutting-edge software to develop an AI machine learning epigenetic application. This app is designed to enhance health, wellness, and longevity by leveraging Foxo's proprietary epigenetic biomarker technology.
Epigenetic biomarkers are changes in gene expression that can provide valuable insights into a person's health status. By integrating these biomarkers with AI technology, Foxo aims to create personalized health solutions that could potentially transform the healthcare industry.
The license granted to Foxo Technologies is limited to the U.S., Canada, and Mexico. This regional focus will allow the company to tailor its application to the specific health needs and challenges of these territories.
The Future of Health Tech
This partnership between Foxo Technologies and KR8 AI Inc. has the potential to redefine the landscape of health technology. By combining AI with epigenetic biomarker technology, they can develop a health application that not only enhances wellness but also extends longevity.
This agreement is a testament to the innovative spirit of both companies. It sets a new standard for how AI can be used to advance health and wellness. We look forward to witnessing the positive impact this collaboration will have on the health tech industry and the lives of people in the U.S., Canada, and Mexico.
Disclaimer: This article includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.
As an investor it's important to stay updated with major news. Get real-time stock market alerts and research by creating an account here.
Sources: